Gene Therapy Manufacturing Hurdle: Sponsors Unwilling To Share ‘Secret Sauce’

US FDA’s Peter Marks says companies are not exchanging information about adenoviral factors, which is probably slowing down the field. He describes NIH's plans for a bespoke gene therapy consortium for vector generation and continued efforts for regulatory harmonization.

Secret sauce of Gene therapy
Gene therapy companies are not exchaning manufacturing information they regard as secret sauce

The willingness of biopharma companies to share information can be crucial in advancing treatments in a new field. That's the message that the US Food and Drug Administration's Peter Marks conveyed in a meeting on the current state of gene therapy.

Marks, director of FDA's Center for Biologics Evaluation and Research, said the biggest sticking point in producing gene therapy products...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Cell & Gene Therapies

More from Advanced Technologies